The Role of Second-Line Chemotherapy in Colorectal Cancer

Oncology Research and Treatment

Volumn 20, Issue 4, 1997, Pages 288-294

  Schmoll, H J ^a   Buchele T ^a   Schober C ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Colorectal cancer; Palliative treatment; Salvage treatment; Second line chemotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG INDICATION; DRUG RESISTANCE; DRUG RESPONSE; HUMAN; NEUROTOXICITY; PALLIATIVE THERAPY; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 0030771521     PISSN: 22965270     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218958     Document Type: Article

References (51)

1. Scheithauer W, Rosen H, Kornek G, Sebesla C, Depisch D: Randomised comparison of combination chemotherapy plus supportive care with supportive are alone in patients with metastatic colorectal cancer. Br J Cancer 1993;306:752-755.
2. Kohnc-Wtimpncr CH, Schmoll HJ, Harstrick A, Rustum Y: Chemotherapeutic strategies in metastatic colorectal cancer. An overview of current clinical trials. Sem Oncol 1992:19:105-125.
3. Hejna M, Kornek G, WeinlSnder G, Ftegl M, Scheit-hauer W: Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Acta Chir Austriaca 1995:115:21:abstr 52.
4. Harstrick A, Gonzales A, Hoffmann A, Schlcucker N, Vanhoefer U, Rustum Y, Seebers S, Wilke H: Development and characterisation of human gastric, colon and breast carcinoma cell lines resistant to 5-FU using various, clinically relevant application schedules Proc Am Assoc Cancer Res 1995;66:abstr 1889.
5. Aschele C, Sobrero A, Faderan A, Bertino JR: Novel mechanism(s) of resistance to 5-Fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules Cancer Res 1992:52:1855-1864.
6. Wang FS, Aschele C, Sobrero A, Chang YM, Bertino JR: Decreased folylpolyglutamate synthetase expression: A novel mechanism of fluorouracil resistance. Cancer Res 1993;53:3677-3680.
7. Ducreux M, Rougier P, Voni R, Gautrin S, Kac J, Armand JP, Bonnay M: Lack of relationship between plasma concentration and clinical parameters in patients with metastatic colorectal cancer treated with prolonged infusion of 5-fluorouracil and oral leuco-vorin. Proc Am Ass Cancer Res 1996:37:408. abstr 2782.
8. Logue JP, Kiltie AH, James RD, Wilkinson PM: Continuous infusion of 5-Fluorouracil in patients with progressive metastatic colorectal carcinoma following intermittent 5FU based chemotherapy. Proc Am Soc Clin Oncol 1995:14. abstr 571.
9. Lim HL, Wong JE, Wang TL, Kong IIL: Salvage Chemotherapy in previously treated mestatic colorectal cancer. Proc Am Soc Clin Oncol 1995; 14: abstr 505.
10. Streit M, Stremetzne S, Jachdc U, Zwiebel FM, Kerz H, Hollenberger P, Strohbach F, Thiel F, Kreuser ED: A multicenter phase II clinical and pharmacokinetic trial of prolonged continuous infusion of 5-Fluorouracil and Folinic acid in patients with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 1996:15: abstr 554.
11. Curd H, Garufi C, Focan C, Bousquet J, Dcpres P, Mita A, Zidano A, Pczet D, Tcrzoli L, Chollet P, Lévi F: A phase 1-11 assessment of five-day chrono-modulated 5-Fluorouracil - Leucovorin against metastatic colorectal cancer. Proc Am Soc Clin Oncol I996;15:abstr 1708.
12. Bjarnason GA, Marsh R, Chu NM, Hrushesky WJ, Kerr I: Phase II study of 5-Fluorouracil and Leucovorin by a 14 day circadian infusion in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1956:15: abstr 543.
13. Bajelta E, Di Bartolomeo M, Somma L, Vicario G, Celio L, Bignami P, Bandieri E, Baldini M: Doxiflu-ridine in patienls with 5-FU resistant colorectal cancer. Proc ECCO. 1995; abstr 705.
14. Ardalan B, Restrepo A, Deng Z, Sridhar KS, Feun L, Richman S, Sparling L, Watson C, Triplett N: Phase 1-11 of high dose 24-hour infusion of Fluoro-deoxyuridine (FldR) in patients with colorectal cancers (previously failed S-Fluorouracil). Proc Am Soc Clin Oncol 1996: abstr 450.
15. Ardalan B, Chua L, Ttan EM, Roddy R, Stridhar K, Benedetto P, Richmann S, Legaspi A, Waldmann S, Morell L, Feun L, Savaraj N, Livingstone A: A phase II study of weekly 24-hour infusion with higlt-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991:9:625-630.
16. Jaeger E, Klein O, Wächter B, Müller B, Braun U, Knuth A: Second line treatment with high-dose 5-Fluorouracil and Folinic acid in advanced colorectal cancer refractory to standard-dose 5-Fluoroura-cil treatment. Oncology 1995:52:470-473.
17. Weh IIJ, Wilke UJ, Dierlamm J, Klaassen U, Sieg-mund R, Illigcr HJ, Schalhorn A, Krcuser ED, Hil-genfeld U, Steinke B, Weber W, Burkhard O, Zoller À, Pfitzner J, Subert R, Kriebel R, Hossfeld DK: Weekly therapy with Folinic acid and high-dose 5-Fluorouracil 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994:5:233-237.
18. Loefflcr TM, Lluck L, Hausamen TU: Weekly high-dose continous infusion fluorouracil. leucovorin and intcrfcron-alpha (L1F) as second-line chemotherapy in metastatic colorectal cancer. Proc ESMO 1994. p 55 (abstr 275).
19. Lorenz M, Staib-Sebler E, Gog C, Pctrowsky H, Encke A: Intravenous weekly high-dose infusion of S-fluorouracil and folinic acid in pretreated patients with metastatic colorectal cancer. Onkologie 1997: 20:222-225.
20. Izzo J, Fandi A, Villalobos W: Low-dose protracted continuous 5-Fluorouracil infusion in solid tumors J Inf Chcmother 1995:4:135-139.
21. Pérez J, Lacava J, Sabatini C, Dominguez M, Rodriguez R, Barbieri M, Cuevas M, Romero-Acuna L, Romero-Acuna J, Langhi M, Amato S, Marrone N, Salvadori M, Ortiz E, Leone B, Vallejo C, Machiavelli M, Romero A: Interferon and 5-Fluorouracil as second line therapy in advanced colorectal cancer: phase II study. Proc Am Soc Clin Oncol 1996:15: abstr 529.
22. Penel N, Adenis A, Fournier C, Maes-Dombrowski P, Carlier D, Bonneterre J: ECF regimen as salvage treatment in patients with progressive metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 1996:15: abstr 533.
23. Tsavaris N, Tentas K, Bacoyiannis C, Katsikas M, Sakelaropoulos N, Komas C, Daliani D, Kosmidis P: 5-Fluorouracil. Folinic acid and Cisplatin in advanced colorectal cancer: A pilot study. Anticancer Drugs 1995:6:599-603.
24. Mathe G, Kidani Y, Scgiguchi M: Oxalato-platinum or L-OHP. a third generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cisplatinum and carboplatinum. Biomed Pharmacother 1989:43:237-250.
25. Pendvala L, C'reaven PJ, Shah G, Molnar MV, Grandjean EM: In vitro cytotoxicity studies of Oxa-liplatin in human tumor cell lines Proc Am Assoc Cancer Res 1991:32: abstr 410.
26. Fojo T, Myers T, Tanimura H: Phenotypic aspects of platinum resistance. Proc 7th Int Symposium on platinum and other metal coordination compounds in cancer chemotherapy (ISPCC’95). 1995. abstr 171.
27. Diaz-Rubio E, Zaniboni A, Gastiaburu J, Labianca R, Cortes-Funes H, De Braud F, Boni C, Vignoud J: Phase II multicentric trial of Oxaliplatin as first line chemotherapy in metastatic colorectal carcinoma. Proc Am Soc Clin Oncol 1996:15: abstr 468.
28. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu J, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, François E, Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M: Two consecutive phase II studies of Oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996:7:95-98.
29. Lévi F, Pcrpoint B, Garufi C, Foran C, Chollct P, De-pres-Brummer P, Zidani R, Brienza S, Itzhaki M, la-cobelli S, Kunstlinger F, Gastiaburu J, Misset JL: Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-dav continuous venous infusion at circadian rhythm modulated rale. Eur J Cancer 1993:29A.9:1281-1284.
30. de Gramont A, Vignoud J, Tournigand C, Louvet C, Varctte C, Raymond C, Krulik M: Oxaliplatin with high-dose Folinic acid and 5-Fluorouracil 4Sh infusion in pretreated metastatic colorectal cancer. Proc ECCO. 1995; abstr 716.
31. Lévi F, Missel JL, Brienza S, Adam R, Metzger G, Itzhaki M, Caussancl JP, Kunstlinger F, Lecouturier S, Descorps-Declère A, Jasmin C, Bismuth H, Rein-berg A: A chronopharmacologic phase II clinical trial with 5-fluorouracil. folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump, High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992:69:893-900.
32. Garufi C, Brienza S, Bcnsmain MA, Missel JL, Bertheaull-Cvitkovic A, Terzoli E, Lévi F: Addition of Oxaliplatin to chronomodulated 5-Fluorouracil and folinic acid for reversal of acquired chemoresis-tance in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1995:14: abstr 446.
33. Louvet C, Bleiberg H, Gamelin E, François E, Andre T, Extra JM, Noie F, Bensmaine MA, Itzhaki M, Brienza S, Cvilkovic E: Oxaliplatin (L-OHP) synergistic clinical activity with 5-Fluorouracil in FU resistant colorectal cancer patients is independent of FU ± Folinic acid. Proc Am Soc Clin Oncol 1996:15: abstr 467.
34. Soulié P, Raymond E, Misset JL, Cvilkovic E: Oxaliplatin: Upate on a active and safe Dach Platinum complex; In Pinedo HM, Schornagel JH (eds.): Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. New York. Plenum Press, 1996. pp 165-174.
35. Bertheault-Cvitkovic F, Jami A, Ithzaki M, Depres Brummer P, Brienza S, Adam R, Kunstlinger F, Bismuth H, Misset JL, Lévi F: Biweekly intensified ambulatory chronomodulated chemotherapy with Oxaliplatin. 5-Fluorouracil and Folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 1996:14:2950-2958.
36. Pilot HC, Wender D, O’Conell MJ, Wieand HS, Mailliard JA: A phase II trial of CPT-11 (Irinotecan) in patients with metastatic colorectal carcinoma: A North Central Cancer Treatment Group study. Proc Am Soc Clin Oncol 1994:13:197. abstr 573.
37. Rothenberg ML, Eckardl JR, Kuhn JG, Burris HA, Nelson J. Hilsenbcck SG. Rodriguez GI, Iliurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf U, Von-Hoff DD: Phase II Trail of Irinotecan in Patients with progressive or rapidly recurrent Colorectal Cancer. J Clin Oncol 1996:14: 1128-1135.
38. Shimada Y, Yoshino M, Wakui A, Nakao I, Futasuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N: Phase II study of CPT-11, a new camptothccin derivale. in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993:11:909-913.
39. Rougier R, Bugat R, Douillard JY, Culine S, Sue E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M: Phase II study of Irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients prelreated with fluorouracil-bascd chemotherapy. J Clin Oncol 1997:15:251-260.
40. Van Cutsent E, Cunningham W, Ten Bokkel, Hui-nink W, Dirix L, Punt C, Alexopoulos C, Cote C, Blanc C. Bleibcrg H: Irinotecan (CPT-11) multicenter phase II study in colorectal cancer patients with documented progressive disease on prior 5-FU: Preliminary results. Proc Am Soc Clin Oncol 1996; 15:abstr 230.
41. Droz JP, Marly M, Douillard JY, Ychou M, Rougier P, Bugat R, Brunet R, Seitz JK, Mousseau M, Burki F, Piedhois P, Mcry-Mignard D, CPT-11 in 5-FU-re-sistant colorectal cancer: Management of delayed diarrhea, European Society of Medical Oncology (ESMO). 21th annual meeting. Vienna. Austria 19%. abstractbook. Abstr. 223.
42. Cascinu S, Fcdcli A, Luzi-Fedcli S, Catalano G: Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-Fluorouracil/Leucovorin combination. J Chemother 1992:4:46-49.
43. Adenis A, Carlier D, Darloy F, Pion JM, Bonneterre J, Demaille A: Cytarabinc and Cisplatin as salvage therapy in patients with metastatic colorectal cancer who failed 5-Fluorouracil + Folinic acid regimen. French Northern Oncology Group. Am J Clin Oncol 1995;18:158-160.
44. Zaniboni A, Labianca R, Panccra G, Barni S, Fron-lini L, Marini G, Luporini G: Oral Etoposide as second-line chemotherapy for colorectal cancer: A GISCAD study. Gruppo ltaliano Studio Carcinomi Apparato Digerente. J Chemother 1995;7:246-248.
45. Stuart K, Posner M, Campbell K, Huberman M: Cisplatin and chronic oral Etoposide as salvage therapy for advanced colorectal carcinoma. Am J Clin Oncol 1995:18:300-302.
46. Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Mere-galli S, Fossati V, Famagalli L, Brivio F, Tancini G: A randomized study of low-dose subcutaneous Intcr-leukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-Fluorouracil and folates Oncology 1995:52:243-245.
47. Welt S, Scott AM, Divgi CR: Phase I-ll study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1996;14:1787-1797.
48. Pai LH, Wiltes RE, Setser A, Willingham MC, Pastan I: Phase I study of the immunoloxin LMB-1. an anti-cancer murine Mah B3. coupled to a recombinant form of pseudomonas exotoxin PE38. Proc Am Soc Clin Oncol 1996:15: abstr 1528.
49. Brohei D, Azagra-Soria S, Ceutcrick M, Baudoux M: Protracted 5-Fluorouracil infusion with weekly low doses of Folinic acid in metastatic colon cancer. 8. European Cancer Conference (ECCO). Paris. France. 1995: abstractbook. abstr 714.
50. Levi F, Soussan A, Adam R, Caussanel JP, Metzger G, Jasmin C, Bismuth H, Smolensky M, Missel JL: A phase I II trial of five-day continuous intravenous infusion of 5-Fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer. J Inf Chemother 1995;5(supp 1):153-158.
51. Levi F, Giacchetti S, Adam R, Zidani R, Metzger Ci, Misset JL: Chronomodulation of chemotherapy against metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Eur J Cancer 1995:31 A: 1264-1270.